Índice Bovespa

US Dollar vs BRL

Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.

Cadastre-se

AUPH Aurinia Pharmaceuticals Inc

5,275

-0,255 (-4,61%)

Última atualização: 14:38:39

Atrasado em 15 minutos

Form 3 - Initial statement of beneficial ownership of securities

Aurinia Pharmaceuticals (NASDAQ:AUPH)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024

Click aqui para mais gráficos Aurinia Pharmaceuticals.

Aurinia Pharmaceuticals (NASDAQ:AUPH)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024

Click aqui para mais gráficos Aurinia Pharmaceuticals.

Notícias Aurinia Pharmaceuticals Inc

Form 4 - Statement of changes in beneficial ownership of securities
Quarta, 22 de Maio de 2024 (22 horas atrás) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Quarta, 22 de Maio de 2024 (22 horas atrás) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Quarta, 22 de Maio de 2024 (22 horas atrás) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Quarta, 22 de Maio de 2024 (22 horas atrás) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Quarta, 22 de Maio de 2024 (22 horas atrás) • Edgar (US Regulatory)

Analysis Showing LUPKYNIS® is a Cost-Effective Treatment for Lupus Nephritis Presented at National Kidney Foundation’s Spring Clinical Meeting 2024
Terça, 14 de Maio de 2024 (1 semana atrás) • Business Wire

Aurinia Presents Data Reinforcing LUPKYNIS® Safety and Efficacy for People with Lupus Nephritis at Congress of Clinical Rheumatology East 2024
Quinta, 9 de Maio de 2024 (2 semanas atrás) • Business Wire

Aurinia Will Attend 2024 RBC Capital Markets Global Healthcare Conference
Terça, 7 de Maio de 2024 (2 semanas atrás) • Business Wire

Aurinia Pharmaceuticals Reports First Quarter 2024 Financial and Operational Results
Quinta, 2 de Maio de 2024 (3 semanas atrás) • Business Wire

Aurinia Underscores Enduring Commitment to People Living with Lupus Nephritis Through Innovative Advocacy and Education Initiatives for Lupus Awareness Month
Quarta, 1 de Maio de 2024 (3 semanas atrás) • Business Wire

The U.S. Food & Drug Administration (FDA) Approves Updated LUPKYNIS® (voclosporin) Label to include Long-Term Data from the AURORA Clinical Program
Terça, 30 de Abril de 2024 (3 semanas atrás) • Business Wire

UPDATE: New Aurinia Presentation Details at the 2024 Bloom Burton & Co. Healthcare Investor Conference
Terça, 16 de Abril de 2024 (1 mês atrás) • Business Wire

Mais Notícias de Aurinia Pharmaceuticals Inc

NLBNPIT1XIY6 20240621 40

NLBNPIT1Z646 20991231 31...

Belgische Staat

Planrock Market Neutral ...

Advisorshares Alpha Dna ...

Delayed Upgrade Clock

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições